Version 1
: Received: 13 April 2020 / Approved: 15 April 2020 / Online: 15 April 2020 (09:50:21 CEST)
How to cite:
Kumar, S.; Chmura, S.; Robinson, C.; Lin, S.H.; Gadgeel, S.M.; Donington, J.; Feliciano, J.; Stinchcombe, T.E.; Werner-Wasik, M.; Edelman, M.J.; Moghanaki, D. Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic. Preprints2020, 2020040236. https://doi.org/10.20944/preprints202004.0236.v1
Kumar, S.; Chmura, S.; Robinson, C.; Lin, S.H.; Gadgeel, S.M.; Donington, J.; Feliciano, J.; Stinchcombe, T.E.; Werner-Wasik, M.; Edelman, M.J.; Moghanaki, D. Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic. Preprints 2020, 2020040236. https://doi.org/10.20944/preprints202004.0236.v1
Kumar, S.; Chmura, S.; Robinson, C.; Lin, S.H.; Gadgeel, S.M.; Donington, J.; Feliciano, J.; Stinchcombe, T.E.; Werner-Wasik, M.; Edelman, M.J.; Moghanaki, D. Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic. Preprints2020, 2020040236. https://doi.org/10.20944/preprints202004.0236.v1
APA Style
Kumar, S., Chmura, S., Robinson, C., Lin, S.H., Gadgeel, S.M., Donington, J., Feliciano, J., Stinchcombe, T.E., Werner-Wasik, M., Edelman, M.J., & Moghanaki, D. (2020). Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic. Preprints. https://doi.org/10.20944/preprints202004.0236.v1
Chicago/Turabian Style
Kumar, S., Martin J. Edelman and Drew Moghanaki. 2020 "Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic" Preprints. https://doi.org/10.20944/preprints202004.0236.v1
Abstract
Importance: The COVID-19 pandemic is currently accelerating. Patients with locally advanced non-small cell lung cancer (LA-NSCLC) may require treatment in locations where resources are limited and the prevalence of infection is high. Patients with LA-NSCLC frequently present with comorbidities that increase the risk for severe morbidity and mortality from COVID-19. These risks may be further increased by treatments for LA-NSCLC. Observation:We present expert thoracic oncology multidisciplinary (radiation oncology, medical oncology, surgical oncology) consensus of alternative strategies for the treatment of LA-NSCLC during a pandemic. The overarching goals of these approaches are to reduce the number of visits to a healthcare facility, reduce the risk of SARS-CoV-2 exposure, and attenuate the immunocompromising effects of lung cancer therapies. Patients with resectable disease can be treated with definitive non-operative management if surgical resources are limited or the risks of perioperative care are high. Non-operative options include chemotherapy, chemoimmunotherapy, and radiation therapy with sequential schedules. The order of treatments may be based on patient factors and clinical resources. Whenever radiation therapy is delivered without concurrent chemotherapy, hypofractionated schedules are appropriate. For patients who are confirmed to have COVID-19, usually cancer therapies may be withheld until symptoms have resolved with negative viral test results.Conclusions and Relevance: The risk of severe treatment-related morbidity and mortality is significantly elevated for patients undergoing treatment for LA-NSCLC during the COVID-19 pandemic. Adapting alternative treatment strategies as quickly as possible may save lives and should be implemented through communication with the multidisciplinary cancer team.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
